Cellectis quits CAR-T and pivots to ‘in vivo’ gene editing
Published . Updated .
Long a frontrunner in donor-derived cell therapy research, the French biotech cited a shifting landscape in changing course and choosing to offload its lead programs.
Directly affected
- No company is named in this report.
Indirectly affected
- ACHC ACADIA HEALTHCARE COMPANY INC
GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- ASND ASCENDIS PHARMA A/S
GA selected ASND as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- ATYR ATYR PHARMA INC COM NEW
GA selected ATYR as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- BBIO BRIDGEBIO PHARMA INC
GA selected BBIO as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- DVA DaVita HealthCare Partners, Inc.
GA selected DVA as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- GEHC GE HEALTHCARE TECHNOLOGIES I
GA selected GEHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
Price reaction, T-5 to T+3
How far Acadia Healthcare (ACHC) has moved since 14 Sep 2026
Since the first closing price after “Cellectis quits CAR-T and pivots to ‘in vivo’ gene editing,” Acadia Healthcare (ACHC) is +10.34%. The S&P 500 fund (SPY) is +1.21% over the same days, a +9.13% difference versus the market.
Disclosure records for Acadia Healthcare (ACHC) within two months of 14 Sep 2026
- Gilbert Cisneros sell BridgeBio Pharma (BBIO) ($1,001 - $15,000). That is 15 days after publication, inside 30 days. The filing is listed beside the story “Cellectis quits CAR-T and pivots to ‘in vivo’ gene editing.”
- Rohit Khanna buy GE HealthCare Technologies (GEHC) ($1,001 - $15,000). That is 3 days before publication, inside 30 days. The filing is listed beside the story “Cellectis quits CAR-T and pivots to ‘in vivo’ gene editing.”
- Rohit Khanna buy GE HealthCare Technologies (GEHC) ($1,001 - $15,000). That is 42 days before publication, inside 60 days. The filing is listed beside the story “Cellectis quits CAR-T and pivots to ‘in vivo’ gene editing.”
- Rohit Khanna buy GE HealthCare Technologies (GEHC) ($1,001 - $15,000). That is 46 days before publication, inside 60 days. The filing is listed beside the story “Cellectis quits CAR-T and pivots to ‘in vivo’ gene editing.”
- Rohit Khanna buy GE HealthCare Technologies (GEHC) ($1,001 - $15,000). That is 46 days before publication, inside 60 days. The filing is listed beside the story “Cellectis quits CAR-T and pivots to ‘in vivo’ gene editing.”
- Rohit Khanna buy GE HealthCare Technologies (GEHC) ($1,001 - $15,000). That is 53 days before publication, inside 60 days. The filing is listed beside the story “Cellectis quits CAR-T and pivots to ‘in vivo’ gene editing.”
- Rohit Khanna buy GE HealthCare Technologies (GEHC) ($1,001 - $15,000). That is 55 days before publication, inside 60 days. The filing is listed beside the story “Cellectis quits CAR-T and pivots to ‘in vivo’ gene editing.”
- Donald J Trump sell GE HealthCare Technologies (GEHC) ($1,001 - $15,000). That is 59 days before publication, inside 60 days. The filing is listed beside the story “Cellectis quits CAR-T and pivots to ‘in vivo’ gene editing.”
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
Who is named in “Cellectis quits CAR-T and pivots to ‘in vivo’ gene editing”
Companies mentioned with this story
- ACHC Acadia Healthcare
For “Cellectis quits CAR-T and pivots to ‘in vivo’ gene editing,” Acadia Healthcare (ACHC) is linked, with no stored direction, medium confidence. Reason on file: GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- ASND Ascendis Pharma A/S
Ascendis Pharma A/S (ASND) is linked, with no stored direction, medium confidence in the 14 Sep 2026 story “Cellectis quits CAR-T and pivots to ‘in vivo’ gene editing.” Reason on file: GA selected ASND as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- ATYR aTYR PHARMA
aTYR PHARMA (ATYR) is linked, with no stored direction, medium confidence in the 14 Sep 2026 story “Cellectis quits CAR-T and pivots to ‘in vivo’ gene editing.” Reason on file: GA selected ATYR as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- BBIO BridgeBio Pharma
BridgeBio Pharma (BBIO) is linked, with no stored direction, medium confidence in the 14 Sep 2026 story “Cellectis quits CAR-T and pivots to ‘in vivo’ gene editing.” Reason on file: GA selected BBIO as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- DVA Davita
In “Cellectis quits CAR-T and pivots to ‘in vivo’ gene editing,” Davita (DVA) is linked, with no stored direction, medium confidence. Reason on file: GA selected DVA as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- GEHC GE HealthCare Technologies
For “Cellectis quits CAR-T and pivots to ‘in vivo’ gene editing,” GE HealthCare Technologies (GEHC) is linked, with no stored direction, medium confidence. Reason on file: GA selected GEHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
How “Cellectis quits CAR-T and pivots to ‘in vivo’ gene editing” reaches Acadia Healthcare (ACHC)
On 14 Sep 2026, “Cellectis quits CAR-T and pivots to ‘in vivo’ gene editing” is the story that connects Acadia Healthcare (ACHC) to this story.
For Acadia Healthcare (ACHC), the reason on file says GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
Ascendis Pharma A/S (ASND) is here too. Its reason reads: GA selected ASND as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
Dates in the story, and the Acadia Healthcare (ACHC) price range
ACHC traded between 26.75 and 32.03 across 20 sessions. The latest close on file is 30.20. ASND traded between 219.69 and 240.84 across 20 sessions. The latest close on file is 229.99. ATYR traded between 0.17 and 0.41 across 20 sessions. The latest close on file is 0.17.
How strong the case is around Acadia Healthcare (ACHC)
100 out of 100
“Cellectis quits CAR-T and pivots to ‘in vivo’ gene editing” scores 100 out of 100. The score uses 6 linked companies.